Recently, cancer immunotherapy including monotherapy1 or combination therapy with anti-PD-1 antibody2 showed better therapeutic effect than molecular-targeted therapies for metastatic renal cell carcinoma (RCC) patients. This evidence concerns the gene PDCD1 and cancer.